|
|
|
|
|
|
-
Seattle Genetics Announces FDA Acceptance Of ADCETRIS Supplemental BLA For Filing
5/14/2013
|
|
|
-
Seattle Genetics Post Q1 Loss Per Share Of $0.14 Vs. Loss $0.11 Year Ago
5/7/2013
|
|
|
|
|
|
|
-
Seattle Genetics Submits Supplemental BLA To FDA For Retreatment And Extended Duration Of Therapy With ADCETRIS
3/18/2013
|